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Free pentosidine and neopterin as markers of progression rate in diabetic
nephropathy.
Background. Patients with diabetic nephropathy experience a progres-
sive and usually inexorable decline in renal function. The presence of the
structurally defined advanced glycation end product (AGE) pentosidine
on tissue and circulating proteins has been correlated with the severity of
diabetic complications.
Methods. To delineate a role for this AGE in the progression of diabetic
nephropathy, glycohemoglobin and free and protein-bound pentosidine
were measured in baseline stored serum and urine from a subgroup of
patients with diabetes mellitus and proteinuria originally followed by the
Collaborative Study Group Trial. To delineate a potential role for an
immune-activation response to AGEs, the inflammatory markers, inter-
leukin-6 (IL-6), C-reactive protein (CRP), and the monocyte activation
marker neopterin were also measured at baseline. The patients chosen
represented 67 subjects whose creatinine levels had “doubled” over the
course of the study whether or not they later were treated with captopril,
and 67 paired “non-doublers.”
Results. Baseline disease activity, as manifested by glycohemoglobin,
serum creatinine and degree of proteinuria was equal in the two groups,
as was protein-bound pentosidine and the immune-markers IL-6 and
CRP. At baseline the “doublers” as compared to the “non-doublers” had
elevated serum levels of free pentosidine and neopterin. Baseline in-
creases in these two parameters were also associated with an increased
rate of “doubling” of serum creatinine by the proportional hazards
method.
Conclusion. Differences in individual responsiveness to AGEs, as
manifested by either the production of free pentosidine or its release from
a protein-bound form, and by evidence of monocyte/macrophage activa-
tion, are associated with progression of diabetic nephropathy.
Renal disease is one of the most serious long-term
complications that can develop in patients with diabetes
mellitus. In the United States, about 30% of the patients
treated for end-stage renal failure have diabetic nephrop-
athy [1], which develops in up to 45% of patients with
diabetes [2, 3]. The clinical onset of nephropathy is marked
by microalbuminuria (an albumin excretion rate of more
than 30 mg/day but less than 300 mg/day). Over a period of
one to five years following the onset of microalbuminuria,
frank proteinuria usually develops, frequently with associ-
ated hypertension [4]. Patients with diabetic nephropathy
experience a progressive and usually inexorable decline in
renal function, although the rate of deterioration can be
significantly slowed by the treatment of associated hyper-
tension. The special role of angiotensin converting enzyme
(ACE) inhibitors in slowing progression of diabetic ne-
phropathy independent of its effect on blood pressure has
been emphasized in a number of recent studies [5–7].
Another factor associated with the progression of dia-
betic nephropathy is the degree of control of hyperglyce-
mia, as demonstrated recently in the Diabetes Complica-
tions and Control Trial [8]. The patient group treated with
strict glycemic control experienced a marked reduction in
the development of microalbuminuria. The mechanisms by
which hyperglycemia results in nephropathy and other
1 The Collaborative Study Group.
Clinical Coordinating Center. Rush Presbyterian St. Luke’s Medical
Center (Chicago, IL). Principal Investigator, Edmund J. Lewis; Project
Coordinator and Director of Central Laboratory, Richard Rohde.
Biostatistical Coordinating Center. George Washington University
(Washington, D.C.). Principle Investigator, Raymond P. Bain; Co-Princi-
pal Investigators, J.K. Evans, T.R. Turlington, and P.K. Burrows.
Collaborating Investigators and Clinics. J. Sheehan (Case Western
Reserve University, Cleveland, OH); M. Pohl (Cleveland Clinic, Cleveland,
OH); T. Berl (University of Colorado, Denver, CO); J. Lemann, Jr., S.
Blumenthal, and S. Bresnahan (Medical College of Wisconsin, Milwaukee,
WI); L. Hebert and N.S. Nahman, Jr. (Ohio State University, Columbus,
OH); R. Rodby (Rush-Presbyterian/St. Luke’s Medical Center, Chicago, IL);
J. McGill (Washington University, St. Louis, MO); F. Whittier (Affiliated
Hospitals of Canton, Canton, OH); D. Cattran (University of Toronto,
Toronto, Ontario, Canada); J. Hano (Loyola Medical Center, Maywood,
IL); L. Hunsicker (University of Iowa, Iowa City, IA); D. Maxwell (Indiana
University, Indianapolis, IN); J. Porush and S. Spitalewitz (Brookdale
Hospital Medical Center, Brooklyn, NY); K. Shapiro (Nyack Hospital, New
York, NY); S. Adler (Harbor-UCLA Medical Center, Torrance, CA); N.
Tolchin (Nephrology & Internal Medicine Specialists, P. C., Syracuse, NY);
L. Svetkey (Duke Hypertension Center, Durham, NC); Z. Sharon and B.
Rausenbaum (Atlanta Nephrology Referral Center, Decatur, GA); J. Breyer
and G. Shulman (Vanderbilt University, Nashville, TN).
Key words: diabetic nephropathy, pentosidine, advanced glycation end
products, neopterin, diabetic complications.
Received for publication December 8, 1997
and in revised form February 6, 1998
Accepted for publication February 12, 1998
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54 (1998), pp. 193–202
193
diabetic complications are not well defined. A growing
literature has associated the accumulation of advanced
glycation end products (AGEs) on proteins with the patho-
genesis of diabetic complications. The nonenzymatic reac-
tion of a reducing sugar (such as glucose) and the amine
group of a protein is termed the Maillard or “browning”
reaction. The first step in this reaction leads to the forma-
tion of Amadori products such as glycohemoglobin. The
Amadori reaction is reversible, and these products do not
normally accumulate. However, Amadori products are the
precursors of covalently bound structures on proteins
called advanced glycation end products [9, 10]. In patients
with diabetes, markedly elevated levels of AGEs accumu-
late on tissue and circulating proteins [11]. In animal
models, injecting AGEs into the circulation can induce
physiologic and morphologic changes typical of diabetes
[12].
The structurally defined adduct pentosidine was one of
the first AGEs to be isolated from tissue, and has been
demonstrated in tissue and plasma proteins of patients with
diabetes [13]. Skin pentosidine levels have been correlated
with the severity of diabetic complications [14]. Further,
pentosidine in glomerular basement membranes may play a
pathophysiologic role in diabetic nephropathy [15, 16].
Plasma levels of both protein-bound and -free pentosidine
increase with loss of renal function [17, 18], and both forms
can be recovered from the urine [19, 20]. In a group of
patients with renal insufficiency unrelated to diabetes, we
have demonstrated that serum levels of pentosidine are
most positively correlated with the monocyte activation
marker neopterin, compared with other markers of im-
mune function [21]. We interpreted this finding as evidence
that monocyte activation may play a significant role in the
physiologic response to AGE accumulation. To delineate a
role for these pathways in the progression of diabetic
nephropathy, we measured an Amadori precursor (glyco-
sylated hemoglobin), both the protein-bound and -free
form of the AGE pentosidine, and the immune markers
(IL-6, C-reactive protein and neopterin). These measure-
ments were performed in the baseline stored serum and
urine from a subgroup of patients enrolled in the Collab-
orative Study Group’s Trial of captopril in type 1 diabetic
nephropathy [5]. The main endpoint of the Collaborative
Study Group Trial was doubling of baseline serum creati-
nine. The availability of prospectively collected baseline
samples from this trial provided an opportunity to compare
patients with a poor outcome (“doublers”) to those with a
better outcome (“non-doublers”), whether or not the pa-
tients were subsequently treated with the ACE-inhibitor
captopril.
METHODS
Sample selection
The original study was a prospective, double-blind, ran-
domized clinical trial performed in 30 centers to assess the
effect of angiotensin-converting enzyme inhibition (capto-
pril) in patients with insulin-dependent diabetes mellitus
(IDDM) and diabetic nephropathy [5]. In addition to a
clear effect of therapy, this four year study identified two
independent baseline predictors of progression of renal
failure: serum creatinine and total urinary protein [22]. Of
the 409 patients who participated in the original trial, a
subgroup of 67 individuals were identified who demon-
strated doubling of the serum creatinine (whether treated
with captopril or not) within the study period. These
“doublers” were then matched for treatment, initial serum
creatinine and 24-hour urine protein with a subgroup of
“non-doublers.” Samples of urine and serum were stored at
270°C at the initiation of the Collaborative Study Group
Trial before treatment with captopril or placebo. An addi-
tional 10 sets of samples were obtained at the time of
doubling of serum creatinine, whether or not the patients
were treated by captopril. These samples were matched
with 10 sets of samples from “non-doublers” obtained at
paired times. All samples were coded at Rush-Presbyteri-
an-St. Luke’s Medical Center and assayed in a blinded
fashion by the laboratory at Case Western Reserve Univer-
sity (CWRU).
Clinical laboratory data
Measurements of glycosylated hemoglobin, urine and
serum creatinine, and urine protein were performed in the
central clinical laboratory at Rush-Presbyterian-St. Luke’s
Medical Center using standard clinical laboratory tech-
niques.
Pentosidine
Protein in serum was assayed in a microassay modifica-
tion of the Bradford method using Coomassie brilliant blue
G250 obtained from Bio-Rad Laboratories (Melville, NY,
USA). Protein in urine was measured in the clinical labo-
ratory as described above. Protein (1 mg) from serum and
urine was precipitated on ice with 10% trichloroacetic acid
from Fisher Scientific (Pittsburgh, PA, USA). The pellets
were washed twice with 5% cold trichloroacetic acid and
acid hydrolyzed in 2 ml 6 N HCl for 16 hours at 110°C in
borosilicate tubes with Teflon coated screw caps. Acid was
removed by vacuum centrifugation (Savant, Farmington,
NY, USA). The hydrolyzed pellet was dissolved in 250 ml of
water/0.01 M heptafluorobutyric acid purchased from Sigma
(St. Louis, MO, USA). The hydrolysate was filtered with
0.45 mm nylon microfilterfuge tube obtained from Rainin
(Woburn, MA, USA). The equivalent of 0.4 mg of serum
protein was injected onto a Waters HPLC system (Waters
Division of Millipore, Marlborough, MA, USA). The col-
umn used was a 25 3 0.46 cm C-18 Vydac type 218TP (10
mm) column purchased from Separations Group (Hespe-
ria, CA, USA). The HPLC was programmed with a linear
gradient from 0 to 35 minutes of 10 to 17% acetonitrile
(HPLC grade obtained from Fisher) in HPLC water and
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0.1% heptafluorobutyric acid as a counter ion. Pentosidine
eluted at ;30 minutes as monitored by fluorescence exci-
tation at 335 nm and emission at 385 nm. Pentosidine
prepared according to published procedure was used as a
standard [13]. Results were calculated per mg protein. The
intraassay coefficient of variation for peak area with a
pentosidine standard of 3.75 pmol was 1.9% (range in 6
assays 1.4 to 2.7%). The interassay coefficient of variation
for a sample of urine processed and assayed in each of six
assays was 6.32% (mean 18.62 6 1.18 pmol/mg protein).
The detection limit of the assay is 0.2 pmol.
Free pentosidine
The processing of serum or urine in order to measure
free (not bound to protein) pentosidine was modified from
the methods of Takahashi et al [19, 20]. Serum or urine
were applied to a size-selective filter with 10,000 molecular
weight cut-off, Microcon 10 (Amicon, Beverly, MA, USA),
and centrifuged at 2500 3 g for 90 minutes at 4°C. The low
molecular weight fraction (0.250 ml) was added to 15 ml of
water and applied to a tC18 SepPak column from Waters
Division of Millipore (Marlborough, MA, USA). The 15 ml
volume passed through the column was then dried under a
vacuum and resuspended in 300 ml of 0.01 M heptafluoro-
butyric acid (HFBA) in water purchased from Sigma (St.
Louis, MO, USA) for injection onto the HPLC. Results are
expressed per ml of initial fluid volume.
Separation of serum and urine by size-selective centrif-
ugation was directly compared to the TCA precipitation
method of Takahashi et al in four separate assays. Dupli-
cate samples of serum (0.25 ml) were subjected to TCA
precipitation with 0.75 ml of 10% trichloroacetic acid on ice
followed by centrifugation at 5000 3 g for 15 minutes, or to
filtration using a Microcon 10 as described above. Assays 1
to 3 examined free pentosidine levels in serum from
patients with diabetes and mild renal insufficiency (Corre-
lation value for 3 assays only, r 5 0.92, P , 0.0001). Assay
#4 examined free pentosidine levels in serum samples from
patients with end-stage renal failure on dialysis. There was
an excellent correlation between the two methods (TCA
precipitation and filtration using a 10,000 molecular wt
cut-off filter) for determining free pentosidine (Fig. 1,
correlation value for the four assays together, r 5 0.99, P ,
0.0001). Therefore, because of greater ease in processing,
filtration was used to prepare all the serum samples for the
determination of free pentosidine.
Interleukin-6
Interleukin-6 (IL-6) was measured in a commercially
available ELISA kit (Pelikine Compact human IL-6
ELISA; marketed in the United States by Research Diag-
nostics, Inc., Flanders, NJ, USA). This assay is sensitive to
0.5 to 1 pg/ml. In order to determine the validity of this
assay in frozen (270°C) stored samples, 20 sera that had
been assayed by this ELISA in a previous and unrelated
study were thawed and assayed more than two years later.
There was a small, but insignificant, decrease in the IL-6
signal in the stored samples (mean 5.3 6 0.6 compared
4.9 6 0.9, representing a change of 6.25%). The correlation
between the samples assayed before and after two years of
storage at 270° was r 5 0.846, P , 0.0001, by Pearson
regression analysis. Therefore this assay was deemed valid
for use in stored serum from the Cooperative Trial.
C-reactive protein
C-reactive protein (CRP) was measured using a commer-
cially available enzyme immunoassay (Hemagen Diagnos-
tics, Inc, Waltham, MA, USA). The assay has high repro-
ducibility and accuracy compared to World Health
Organization standards. It has tested validity in stored
samples. The normal range for this assay is 0.6 to 1.9 mg/ml.
Neopterin
Neopterin was measured using a sensitive (to 0.2 ng/ml)
and specific commercially available ELISA, (ICN Pharma-
ceuticals, Inc, Costa Mesa, CA, USA). The normal range of
this assay is 0.3 to 3.0 ng/ml.
Calculations and statistical methods
Creatinine clearance was calculated by the standard
formula UV/P. Excretion of protein-bound pentosidine was
calculated by multiplying the 24-hour urine protein excre-
tion (in g/total volume) by the pentosidine content of the
protein (pmol/mg protein). Excretion of free pentosidine
Fig. 1. Comparison of two methods of determining the free pentosidine
concentration of serum. TCA precipitation and filtration over a 10,000
molecular weight filter were compared in the same samples. There was no
significant difference between the two methods (correlation value, r 5
0.92 for the first 3 assays, P , 0.0001; r 5 0.99, P , 0.0001 for the 4
assays). Symbols are: (1, X, E) assays 1–3; (f) assay 4. Assay #4
examined free pentosidine levels in serum samples from patients with
end-stage renal failure.
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was calculated by multiplying the 24-hour urine volume by
the pentosidine concentration (pmol/ml).
Pearson’s correlation was used to compare methods for
determining free pentosidine, and to compare results of
IL-6 assays on stored samples. Differences between base-
line laboratory values for “doublers” and “non-doublers”
were tested using t-tests without correction for multiple
comparisons. Univariate proportional hazards models that
calculate the unadjusted hazard ratio for doubling (taking
into account time to doubling and censoring) were used to
assess the importance of baseline serum neopterin and free
pentosidine. Multivariate proportional hazards models
were used to assess the independent relationship between
neopterin and serum free pentosidine after adjustment for
age, baseline serum creatinine, baseline proteinuria, and
treatment (that is, captopril or placebo). Optimal prognos-
tic cutpoints for neopterin and free pentosidine were
identified using Receiver Operating Characteristics curves
and rounded to the nearest sensible value using clinical
judgment, specifically for neopterin, a positive test was
defined as .3.0 ng/ml; for free pentosidine, a positive test
was defined as 1.0 pmol/ml. Sensitivity and specificity were
calculated for these definitions using the following formu-
las: sensitivity 5 all positives among “doublers”/all “dou-
blers”; specificity 5 all negatives among “non-doublers”/all
who did not double. Pairwise Pearson’s correlations were
also used to assess important relationships among clinical
characteristics. These data analyses was performed using
Statview 4.5 (Abacus Concepts, Berkeley, CA, USA) on a
Macintosh Centris 650, and Stata 6.01(Stat Corp. College
Station, TX, USA).
RESULTS
Clinical characteristics of “doublers” and “nondoublers”
are shown in Table 1. Because the subjects were matched at
baseline, there were no differences in serum creatinine,
creatinine clearance and 24-hour protein excretion in the
groups of subjects before treatment. To demonstrate the
degree of progression of renal failure over the course of the
study, the end point serum creatinine and creatinine clear-
ances are also included in Table 1. All subjects showed a
progression of renal failure, but the “non-doublers” did not
reach twice baseline by the end of the study period. There
were no baseline differences in clinical characteristics or
results between those who were later treated with captopril
or placebo (data not shown for these parameters). The
clinical characteristics of the 10 study subjects at the time of
doubling, and the matched “non-doublers” are summarized
in Table 2. In this subgroup the “doublers” had significantly
greater 24-hour protein excretion at the end point than the
“non-doublers,” as well as marked differences in end-point
serum creatinine (Fig. 3) and creatinine clearances.
Baseline levels of glycohemoglobin, serum protein-
bound and -free pentosidine, and urinary excretion of
protein-bound and -free pentosidine are shown in Table 3.
The baseline levels of glycohemoglobin (12.5 6 0.4 vs.
12.4 6 0.3%, P 5 0.82), protein-bound pentosidine in
serum (2.2 6 0.2 vs. 2.1 6 0.2 pmol/mg protein, P 5 0.64)
and protein-bound pentosidine urinary excretion (9.8 6 0.9
vs. 8.4 6 1.0, P 5 0.29) did not differ between the
“doublers” and “non-doublers” or by treatment group
(glycohemoglobin, P 5 0.20; serum protein-bound pento-
sidine, P 5 0.30; urine protein-bound pentosidine, P 5
0.69). In contrast, serum free pentosidine (1.4 6 0.2 vs.
0.9 6 0.1 pmol/ml, P , 0.007), and 24-hour free pentosi-
dine excretion (39.6 6 3.8 vs. 27.1 6 3.0 nmol/total volume,
P , 0.01) differed significantly at baseline between the
“doublers” and “non-doublers.” When the data were ana-
lyzed without regard to subsequent “doubling” or “non-
doubling,” there were no baseline differences between
those subjects who were treated with captopril or placebo
for any of the parameters, including serum-free pentosidine
Table 1. Demographic and clinical characteristics of full cohort of
study subjects
“Doubler” “Non-doubler”
Age years 36.5 6 0.9 34.8 6 0.9
Range 21–57 20–49
Sex, M/F 39/28 39/28
Race, C/AA/O 53/13/1 60/7/0
Baseline serum creatinine mg/dl 1.63 6 0.06 1.53 6 0.05
End-pointa serum creatinine mg/dl 3.34 6 0.11 2.69 6 0.23b
Baseline creatinine clearance ml/min 59.2 6 3.4 68.1 6 4.0
End-pointa creatinine clearance
ml/min
27.0 6 1.7 40.8 6 3.8c
Baseline protein excretion
g/24 hr
4.9 6 0.4 4.1 6 0.3
Plus/minus values are means 6 SE. Race is: C, Caucasian; AA, African
American; O, Oriental. Although there were more AA among the
“doublers,” there was no effect of race or sex in the multivariate
proportional hazards model, see text.
a At time of doubling
b P , 0.05, c P , 0.01, comparing “doublers” with “non-doublers” by
t-test
Table 2. Demographic and clinical characteristics of subset of study
subjects examined at time of doubling
“Doubler” “Non-doubler”
Age years 38.7 6 2.9 35.2 6 2.2
Range 26–57 26–46
Sex, M/F 5/5 5/5
Race, C/AA/O 9/1/0 8/2/0
Baselineb serum creatinine mg/dl 1.76 6 0.19 1.61 6 0.15
End-pointa serum creatinine mg/dl 4.05 6 0.44 1.89 6 0.30d
Baselineb creatinine clearance
ml/min
48.3 6 10.0 60.8 6 8.0
End-pointa creatinine clearance
ml/min
25.4 6 5.2 45.7 6 14.0c
Baselineb protein excretion g/24 hr 3.9 6 0.7 4.1 6 0.8
End pointa protein excretion g/24 hr 5.0 6 1.1 2.4 6 0.5c
Plus/minus values are means 6 SE. Race is: C, Caucasian; AA, African
American; O, Oriental.
a At time of doubling
b At study initiation
Comparisons by t-test, c P , 0.01, d P , 0.001, comparing “doublers”
with “non-doublers”
Collaborative Study Group: Free pentosidine and diabetic nephropathy196
(1.1 6 0.8 vs. 1.2 6 0.2, P 5 0.45), and 24-hour free
pentosidine excretion (35 6 3 vs. 29 6 4, P 5 0.17).
Although there was no difference between baseline serum
creatinine in the “doublers” and “non-doublers” (Tables 1
and 2), Pearson regression analysis showed creatinine to be
highly correlated with baseline levels of protein-bound (r 5
0.4, P , 0.0001) and free (r 5 0.6, P , 0.0001) pentosidine
in serum across the group as a whole, as well as in the
subgroup at baseline and follow-up (Fig. 2).
Baseline serum levels of the monocyte activation marker
neopterin were significantly different between “doublers,”
and “non-doublers” (3.8 6 0.3 vs. 2.7 6 0.2 ng/ml, P ,
0.001). No such difference was found for the immune
markers IL-6 (2.3 6 0.1 vs. 2.1 6 0.1 pg/ml, P , 0.15) or
CRP (3.7 6 0.6 vs. 3.2 6 0.6 ng/ml, P , 0.001; Table 4).
When the data were analyzed based on eventual treatment
with captopril or placebo (and without regard for subse-
quent “doubling” or “non-doubling” status), no differences
in baseline neopterin (3.3 6 0.2 vs. 3.2 6 0.3, P 5 0.75),
IL-6 (2.1 6 0.1 vs. 2.2 6 0.2, P 5 0.48) or CRP (3.4 6 0.6
vs. 3.6 6 0.7, P 5 0.75) were found. Using Pearson
regression analysis, the monocyte activation marker neop-
terin was highly correlated with baseline levels of serum
free (r 5 0.5, P , 0.0001) and protein-bound (r 5 0.6, P ,
0.0001) pentosidine. No such correlation was found for
IL-6 or CRP.
There was a significant correlation between serum cre-
atinine and serum levels of protein-bound (r 5 0.5, P ,
0.002) and free pentosidine (r 5 0.8, P , 0.0001) in the
subgroup of 20 patients at baseline and at the time of
doubling (Fig. 2). The “doublers” showed a highly signifi-
cant increase in serum creatinine, which was also greater
than the increase shown by the “non-doublers” (Fig. 3A).
Although protein-bound pentosidine levels tended to in-
crease with follow-up, the differences between “doublers”
and “non-doublers” were not significant (Fig. 3B). The
“doublers” demonstrated a marked increase in free pento-
sidine in the follow-up period (Fig. 3C). Baseline levels of
free pentosidine were lower in the “non-doublers” (as also
Table 3. Baseline glycosylated hemoglobin and advanced glycation end
product levels by outcome and treatment group
Assigned to
treatment group
“Doublers” “Non-doublers”
ACE-inhibitor Placebo ACE-inhibitor Placebo
Number 25 42 25 42
Glycohemoglobin
%
13.1 6 0.6 12.2 6 0.5 12.8 6 0.5 12.2 6 0.4
Serum protein-
bound
pentosidine
pmol/mg protein
2.5 6 0.4 2.1 6 0.3 2.3 6 0.4 2.0 6 0.3
Serum free
pentosidine
pmol/ml
1.56 6 0.31 1.27 6 0.15 0.93 6 0.11a 0.92 6 0.10a
24-Hour excretion
protein-bound
pentosidine
nmol/TV
9.7 6 1.7 9.9 6 1.2 7.8 6 2.0 8.6 6 1.2
24 Hour excretion
free pentosidine
nmol/TV
33.4 6 5.4 42.9 6 5.1 24.1 6 4.9 28.8 6 3.9a
Plus/minus values are means 6 SE. Comparisons are by 2 way ANOVA.
a P , 0.01 comparing “doublers” with “non-doublers”
Fig. 2. Regression plots of protein bound and free pentosidine versus
serum creatinine in “doublers” and paired “non-doublers” at baseline
(E) and at time of doubling (F). (A) Protein bound pentosidine (r 5 0.50,
P , 0.002). (B) Free pentosidine (r 5 0.76, P , 0.0001). See Table 2.
Table 4. Baseline immune activation markers by outcome and
treatment group
Assigned to
treatment group
“Doublers” “Non-doublers”
ACE-inhibitor Placebo ACE-inhibitor Placebo
Number 25 42 25 42
Interleukin-6
pg/ml
2.2 6 0.2 2.4 6 0.3 2.0 6 0.2 2.1 6 0.3
C-reactive protein
mg/ml
3.5 6 0.7 4.1 6 0.9 3.3 6 0.9 3.2 6 0.9
Neopterin ng/ml 3.5 6 0.5 3.9 6 0.3 2.8 6 0.4a 2.6 6 0.2b
Plus/minus values are means 6 SE. Comparisons are by 2 way ANOVA.
a P , 0.005, b P , 0.001 comparing “doublers” with “non-doublers”
Collaborative Study Group: Free pentosidine and diabetic nephropathy 197
seen in the larger cohort of 67 pairs of subjects; Table 3). In
addition, at follow-up, the total urinary excretion of free
pentosidine remained lower in the “non-doublers” than in
the “doublers” (Fig. 3D).
Because the simple grouping of patients by their “dou-
bling” or “non-doubling” status did not take into account
differences in times of entry into the study and lengths of
observation, additional statistical analyses were performed.
Based on cut-points determined from the ROC curves,
patients with free pentosidine levels greater than 1.0
pmol/ml and those with neopterin levels above 3.0 ng/ml
reached “doubling” of creatinine at a significantly more
rapid rate, Figures 4 and 5. Serum free pentosidine and
neopterin, and the excretion of free pentosidine were
significant predictors for time to “doubling”, in the propor-
tional hazards model with a single covariate (Table 5). The
multivariate proportional hazards model showed no effect
of adjustment for age, baseline serum creatinine, baseline
proteinuria or eventual treatment regimen (captopril or
placebo; Table 6).
Optimal endpoints for serum free pentosidine (.1 pmol/
ml) and neopterin (.3.0 ng/ml) demonstrated modest
sensitivity and specificity for predicting doubling of serum
creatinine (Table 7). Despite differences in Cumulative
Survival as demonstrated by the Kaplan-Meier plots (Figs.
4 and 5), the predictive value of these parameters was not
strong enough for either parameter to be taken as an
isolated predictor for worsening of diabetic nephropathy,
based on this data set.
DISCUSSION
In this subgroup of patients from the Collaborative Study
Group Trial, serum free pentosidine, 24-hour free pento-
sidine excretion, and serum levels of the monocyte activa-
tion marker neopterin differed significantly at baseline in
those whose serum creatinine levels ultimately doubled
compared with those in a matched group who experienced
a better outcome. At baseline, patients in the two groups
had similar levels of serum creatinine, urinary protein
excretion, glycohemoglobin and protein-bound pentosidine
Fig. 3. Whisker plots showing the 10th, 25th, 50th, 75th and 90th percentile distribution of data obtained at baseline (M) and follow-up (u) in 10 pairs
of “doublers” and “non-doublers” (see Table 2). (A) Changes in serum creatinine (***P , 0.0001 baseline vs. follow-up, †††P , 0.0001 follow-up in
“non-doubler” compared to follow-up in “doubler”). (C) Changes in serum free pentosidine (**P , 0.0004 baseline vs. follow-up, †P , 0.02 baseline
in “non-doubler” compared to baseline in “doubler”). (D) Changes in urinary free pentosidine excretion (†P , 0.05, follow-up in “non-double” vs.
follow-up in “doubler”).
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(in serum and excreted). These results confirm the validity
of the study design by demonstrating that subjects were well
matched at baseline for the degree of diabetic severity and
of renal impairment. Comparing baseline values between
“doublers” or “non-doublers” without adjusting for obser-
vation intervals can introduce bias because of differences in
length of observation throughout the study (the effects of
continuing enrollment and variable lengths of follow-up).
Therefore, the effects of these parameters were examined
in a proportional hazards model. Serum free pentosidine
and neopterin remained highly significant, whereas the
effect of 24-hour free pentosidine excretion was not quite
statistically significant (P 5 0.055; Table 4). Grouping
patients by serum neopterin and free pentosidine “cut-
points” resulted in highly significant differences in survival
curves (Figs. 4 and 5). These results suggest that higher
levels of serum free pentosidine and neopterin may serve as
markers of progression in patients with early nephropathy.
The mechanism underlying this association remains specu-
lative.
Pentosidine is a very stable structure. Its resistance to
acid hydrolysis forms the basis for the quantitative methods
used in this paper. In the laboratory, acid hydrolysis breaks
amino acid bonds, but leaves pentosidine intact for mea-
surement by HPLC. A similar process which could result in
the formation of free pentosidine from protein-bound
pentosidine has not been identified in intact animals. Thus,
the origin of free pentosidine in the circulation, or excreted
into the urine remains unclear. Previous reports have
shown that levels of protein-associated pentosidine and
free pentosidine correlate well across a range of concen-
trations of both forms of the AGE [17, 18]. Nonetheless,
greater than 95% of the pentosidine present in the circu-
lation is tightly bound to protein, with less than 5% existing
as free pentosidine [17, 18]. Pentosidine bound to protein
undoubtedly forms through the Maillard reaction directly
involving that protein. Consistent with previously reported
levels, the range of protein-bound pentosidine found in
these patients with diabetic nephropathy and mild renal
insufficiency is two to four times normal [17, 19, 21].
Although plasma-free pentosidine levels were undetectable
in a group of patients with diabetes and normal renal
Fig. 4. Cumulative survival plots of time to doubling of serum creatinine
in study subjects for serum free pentosidine cut points above (M) and
below (E) 1.0 pg/ml. Difference between groups significant at P , 0.01.
Fig. 5. Cumulative survival plots of time to doubling of serum creatinine
in study subjects for serum neopterin cut points above (M) and below (E)
3.0 ng/ml. Difference between groups significant at P , 0.002.
Table 5. Effect of markers on time to doubling of serum creatinine
Parameter N “Doublers”
Hazard
ratio
Confidence
interval P
Serum free
pentosidine
119 61 1.35 1.11–1.64 0.003
Bound pentosidine
excretion
119 60 1.02 0.98–1.04 0.311
Free pentosidine
excretion
114 54 1.01 0.99–1.02 0.055
Neopterin 128 63 1.15 1.03–1.28 0.012
Proportional hazards used to compare times to doubling taking into
account censoring.
Table 6. Effect of neopterin and free pentosidine on time to doubling
of creatinine in multivariate proportional hazards model
Parameter
Hazard
ratio
Confidence
interval P
Age 0.99 0.96–1.04 0.99
Treatmentc 0.82 0.47–1.43 0.49
Baseline serum
creatinine
1.02 0.48–2.16 0.96
Baseline protein
excretion
1.06 0.99–1.14 0.08
Serum free
pentosidineb
1.49 1.11–1.98 0.007
Neopterina 1.17 0.99–1.37 0.05
a Without free pentosidine in model, neopterin P 5 0.0001, other
parameters NS
b Without neopterin in model, free pentosidine P 5 0.0002, other
parameters NS
c Treatment (captopril vs. placebo)
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function [17], the patients in the Collaborative Study had
mild to moderate renal insufficiency.
Animal studies demonstrate that the kidney plays a key
role in removing circulating AGEs, both clearing AGE
peptides and metabolizing AGE proteins by the endo-
lysosomal apparatus of the proximal tubule [23]. The
kidney has high levels of the enzyme 3-deoxyglucosone
reductase, which is thought to prevent protein glycation in
the presence of the Amadori-derived reactive intermediate,
3-deoxyglucosone [24]. Thus, loss of renal mass might result
in loss of expression of this enzyme leading to accelerated
rates of formation of AGEs. In addition, AGEs themselves
can catalyze further AGE formation as demonstrated in
vitro [25].
Free pentosidine in the circulation may have its origin in
the intestinal absorption of food-associated AGEs. Free
pentosidine can be detected in the plasma of both healthy
and uremic rats fed pentosidine, and there is a consistently
prolonged half-life in rats with renal impairment [17].
Recently, radiolabeled free pentosidine has been shown to
accumulate in the proximal tubule when injected into rats
[26]. Tubular processing of pentosidine, via an endolysoso-
mal pathway may explain this finding, because a greater
percentage of unbound radioactivity appeared in the urine
than was immunoprecipitatable. In contrast, in rats with
tubular dysfunction, the urine contained intact radiolabeled
pentosidine [26]. Thus, impaired renal excretion of free
pentosidine may explain accumulation of this metabolite in
the serum of patients with renal failure. However, impaired
excretion of free pentosidine does not account for the
increased quantity of free pentosidine excreted in the urine
in the presence of renal insufficiency. Therefore, increased
total excretion of free pentosidine in the presence of
diabetes and renal insufficiency suggests increased total
formation of this analyte or of a precursor such as protein-
bound pentosidine [17].
The receptor for AGEs (RAGE) has been isolated and
cloned [27, 28]. It has been identified on an array of cells
including endothelial and smooth muscle cells of the vas-
culature, and on macrophages and lymphocytes [29, 30].
Some workers have suggested that uptake and processing
of protein-bound AGEs by monocytes and macrophages
may provide a pathway for degradation with release of
amino acids and free AGEs [31]. In addition, the increased
cellular oxidant stress induced in cells [32, 33] by the uptake
of AGEs, might lead to a vicious cycle in which accumula-
tion of AGEs is accelerated. One explanation for the
increased total excretion of free pentosidine seen in the
“doublers” is that a vicious cycle involving monocytes and
macrophages resulted in the accelerated formation of
AGEs on proteins, with a further increase in the excretion
of free pentosidine.
To obtain evidence of systemic inflammation, an inflam-
matory cytokine that modulates acute phase reaction pro-
teins (IL-6), a marker of the acute phase reaction (C-
reactive protein), and a monocyte/macrophage activation
marker (neopterin) were measured in the baseline serum
samples. IL-6 is produced by activated monocytes and
macrophages, but also by activated T and B cells and
endothelial cells. Renal insufficiency has been associated
with increases in levels of IL-6 [34, 35], and it has been
shown that IL-6 induces the release of acute phase reac-
tants from the liver [36]. IL-6 may play an important role in
nutritional abnormalities experienced by patients with re-
nal failure [37]. C-reactive protein is one of the major
acute-phase reactants produced in the liver in response to
inflammatory cytokines (IL-6, IL-1b and TNF-a). C-reac-
tive protein is a component of normal serum. Increased
levels function in host defense in a manner similar to
immunoglobulins [38]. Neopterin is a monocyte/macro-
phage product that derives from 7,8-dihydroneopterin
triphosphate, the first intermediate in the biosynthesis of
tetrahydrobiopterin from GTP. Because human monocytes
and macrophages contain low levels of 6-pyruvoyl tetrahy-
drobiopterin synthase, neopterin derivatives accumulate
and, after dephosphorylation, can leak from cells [39]. In
chronic inflammatory and infectious diseases, neopterin
has been found to be a valuable predictor of morbidity and
mortality [40].
The monocyte activation marker neopterin and serum
levels of protein-bound pentosidine have been previously
found to have a strong positive correlation in a group of
patients with renal insufficiency unrelated to diabetes
across a wide range of renal function [21]. In the present
study the baseline level of renal function was controlled,
and there were no baseline differences in serum levels of
protein-bound pentosidine. Therefore, the differences in
baseline neopterin levels demonstrated in this study di-
rectly reflect inter-subject variability with respect to mono-
cyte activation. There was a strong correlation between
neopterin levels and free pentosidine levels in the serum of
these patients with diabetic nephropathy, supporting our
hypothesis that a relationship exists between monocyte
activation and the possible release of free pentosidine from
protein-bound pentosidine by these cells.
In summary, elevated levels of serum free pentosidine,
the total urinary excretion of free pentosidine, and the
Table 7. Predictive value of chosen cut-points for neopterin and free
pentosidine
Sensitivity Specificity
Positive
predictive
value
Negative
predictive
value
Serum free
pentosidine .1.0
pmol/ml
52.2% 59.4% 55.6% 56.2%
Neopterin .3.0
ng/ml
48.4% 71.2% 62.0% 58.8%
Cutpoints for neopterin and for free pentosidine were chosen using
Receiver Operating Characteristic curves and clinical judgment. (See
text.)
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monocyte activation marker neopterin, are correlated with
the rate of progression of diabetic nephropathy. Neopterin
levels are highly correlated with serum-free and protein-
bound pentosidine. In conclusion, differences exist in indi-
vidual responsiveness to the handling and processing of
AGEs that form during the course of diabetes. A more
complete understanding of the nature of such differences
has the potential to open new therapeutic approaches to
the prevention of diabetic nephropathy and other compli-
cations of diabetes mellitus.
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